Summary
This clinical study examined the effectiveness of G-CSF treatment in hospitalised infants presenting with neutropenia. Whilst G-CSF accelerated haematologic recovery, the treatment was associated with increased risk of secondary sepsis and elevated mortality, leading the authors to recommend against routine use of G-CSF in this population.
UK applicability
The findings are directly applicable to UK paediatric and neonatal clinical practice, informing treatment guidelines for neutropenic infants in NHS hospitals and likely influencing prescribing decisions in similar healthcare systems with comparable patient populations.
Key measures
Time to haematologic recovery; incidence of secondary sepsis; mortality rate
Outcomes reported
The study evaluated the effectiveness and safety of granulocyte colony-stimulating factor (G-CSF) treatment in hospitalised infants with neutropenia, measuring time to haematologic recovery and incidence of secondary sepsis and mortality.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.